Watson KE, Dovi WF, Conhaim RL. Evidence for active control of perfusion within lung microvessels. J Appl Physiol 112: 48-53, 2012. First published October 13, 2011 doi:10.1152/japplphysiol.00820.2011Vasoconstrictors cause contraction of pulmonary microvascular endothelial cells in culture. We wondered if this meant that contraction of these cells in situ caused active control of microvascular perfusion. If true, it would mean that pulmonary microvessels were not simply passive tubes and that control of pulmonary microvascular perfusion was not mainly due to the contraction and dilation of arterioles. To test this idea, we vasoconstricted isolated perfused rat lungs with angiotensin II, bradykinin, serotonin, or U46619 (a thromboxane analog) at concentrations that produced equal flows. We also perfused matchedflow controls. We then infused a bolus of 3 m diameter particles into each lung and measured the rate of appearance of the particles in the venous effluent. We also measured microscopic trapping patterns of particles retained within each lung. Thirty seconds after particle infusion, venous particle concentrations were significantly lower (P Յ 0.05) for lungs perfused with angiotensin II or bradykinin than for those perfused with U46619, but not significantly different from serotonin perfused lungs or matched flow controls. Microscopic clustering of particles retained within the lungs was significantly greater (P Յ 0.05) for lungs perfused with angiotensin II, bradykinin, or serotonin, than for lungs perfused with U46619 or for matched flow controls. Our results suggest that these agents did not produce vasoconstriction by a common mechanism and support the idea that pulmonary microvessels possess a level of active control and are not simply passive exchange vessels. pulmonary circulation; microcirculation; vasoconstriction; circulatory control; vasoreactivity ARTERIOLAR VASOCONSTRICTION is generally thought to be responsible for the control of perfusion distribution among microvessels. The latter are considered to function passively and exist solely for the purpose of transvascular exchange. However, there is considerable inferential evidence to suggest that microvessels in the lung may be capable of active control of perfusion through them.
ARTERIOLAR VASOCONSTRICTION is generally thought to be responsible for the control of perfusion distribution among microvessels. The latter are considered to function passively and exist solely for the purpose of transvascular exchange. However, there is considerable inferential evidence to suggest that microvessels in the lung may be capable of active control of perfusion through them.
This evidence includes that of Morel and colleagues (20) who showed that when pulmonary microvascular endothelial cells (PMVECs) grown in culture were exposed to the vasoconstrictors angiotensin II and bradykinin, they contracted enough to deform the silicone rubber substrate on which they were cultivated. These authors also reported that endothelial cells obtained from pulmonary arteries and retinal microvessels did not contract under these conditions, suggesting that the contractile properties of PMVECs were unique to those cells. They speculated that the contractile properties of PMVECs meant that they might have a role in regulating local perfusion in situ.
Additional evidence was provided by Weibel who used electron microscopy to show the presence of pericytes around alveolar septal capillaries (22) . The pericytes resided within the capillary basement membrane and included cell processes that lay close to the adjacent capillary endothelium (mean distance, 30 nm). The processes contained cytoplasmic filaments that Weibel claimed were suggestive of contractile ability.
Kapanci and colleagues (16, 17) demonstrated the presence within alveolar septa of what they termed "contractile interstitial cells." They used immunofluorescence to show that these cells contained actin and myosin microfilaments and concluded that they had a possible role in the regulation of ventilation/ perfusion within individual alveoli. The data of Weibel and Kapanci both suggest that a contractile cell apparatus surrounds lung microvessels.
The known contractile properties of PMVECs, plus the potential contractile properties of pericytes and interstitial cells (which may be indistinguishable), are possible mechanisms by which alveolar microvessel caliber might be actively controlled. Such mechanisms could alter the ability of red cells to flow down the bore of those vessels and are possible ways by which erythrocyte distribution could be controlled at the alveolar level. If these ideas are correct, then a new paradigm of perfusion control within the lung would have to be considered, one that did not depend primarily on the activity of arterioles.
The goal of the studies we describe here was to determine, for the first time, if such control could be demonstrated. Our approach was to inject a bolus of 3 m diameter fluorescent latex particles into the circulation of isolated rat lungs while they were perfused with one of several vasoconstrictors. We reasoned that capillary vasoconstriction would impede the ability of the particles to flow through capillaries and thus reduce their concentrations in the lung's venous effluent. We also believed that such vasoconstriction would uniquely affect the trapping patterns of particles that remained within each lung. Differences in particle effluent concentrations or particle trapping patterns among the vasoconstrictors would suggest that each produced vasoconstriction by a unique mechanism, by either arteriolar or microvascular constriction.
METHODS
The methods we used were approved by the animal research committee of our institution. We used lungs isolated from retired, male breeder Sprague-Dawley rats (450 -550 g), which we anesthetized using isoflurane and killed by exsanguination.
Lung preparation. We perfused isolated rat lungs using methods developed by us previously (6, 8 -10) . Briefly, we removed the heart and lungs en bloc, placed them dorsal side down, and cannulated the trachea, pulmonary artery, and left atrium using polyethylene tubing (PE-200). The lungs were warmed using an incandescent lamp, which produced lung surface temperatures of 33 Ϯ 2°C, and ventilated with air (20 breaths/min) at inflation and deflation pressures of 15 and 5 cmH 2O. We perfused the lungs via the pulmonary artery with a buffered hetastarch solution (1.5% Hespan in PBS; B. Braun Medical). The venous effluent was returned to the arterial reservoir using a roller pump (total recirculated perfusate volume, 40 ml). We set the height of the arterial reservoir so that the perfusate's meniscus was 10 cm above the bottom (dorsal side) of the lung (P PA ϭ 10 cm2O); the venous cannula was set level with the dorsal side of the (P ven ϭ 0 cmH 2O).
Vasoconstriction. Once perfusate flows were stable, we added one of the following vasoactive agents to the perfusate solution of each lung to result in the final concentrations shown: bradykinin, 1.1 ϫ 10 Ϫ8 mM (n ϭ 7); serotonin, 1.8 ϫ 10 Ϫ7 mM (n ϭ 5); angiotensin II, 9.6 ϫ 10 Ϫ7 mM (n ϭ 5); U46619 (thromboxane analog;), 3.6 ϫ 10 Ϫ8 mM (n ϭ 5). We chose these concentrations because each produced similar flow reductions among all treatment groups. We also perfused a set of lungs without vasoconstriction (High Flow; n ϭ 5) and perfused an additional set without vasoconstriction in which we lowered the arterial reservoir until it produced average flows similar to those in vasoconstricted lungs (Low Flow; n ϭ 5). Particle infusion. When vasoconstricted flows were stable, after ϳ20 min, we injected a bolus of 3 m diameter red fluorescent latex particles into the arterial cannula over 30 s (3 ϫ 10 6 particles in 0.5 ml; Invitrogen-Molecular Probes, Eugene, OR). We chose particles of this diameter based on results of previous studies. We will return to this point in the DISCUSSION. The number of particles injected was the largest number we could infuse without impeding perfusate flow. We coated the particles with albumin prior to injection to prevent them from clumping in the presence of perfusate buffers (7) .
At the moment we began particle injection, we placed a tube beneath the venous cannula to begin incremental collection of the venous effluent. We replaced the tube after 30 s and repeated this at 30-s intervals for 5 min. We used a fluorescence activated cell sorter (FACScan; Becton Dickinson, San Jose, CA) to measure the total number of particles within each of the 10 effluent samples collected from each lung and expressed these as a fraction of the total number of particles infused. The perfusate volume in each tube was a measure of the perfusate flow during these timed collections.
When the particle collections were complete, we clamped the arterial and venous cannulas, inflated the lungs to a pressure of 20 cmH2O using compressed air, and maintained them at this pressure for 2 days to allow the lungs to dehydrate. We sliced a sagittal section from the left and right hilum of each dried lung and placed these onto the stage of a confocal microscope where we obtained digital images (650 ϫ 650 m) of trapping patterns of the fluorescent particles within each lung.
Image analysis. We used image analysis methods developed by us to quantify the particle distribution patterns as follows (7) . In four images obtained from each lung (2 left, 2 right), we used public domain software (ImageJ, National Institutes of Health) to obtain the x-y address of each particle within each image. We entered this information into a computer program that used the x-y addresses to divide each image into quadrants (2 ϫ 2). The number of particles within each quadrant was counted, and the mean () and standard deviation ( 2 ) of the counts among the quadrants were calculated and expressed as a ratio ( 2 /) known as the dispersion index (7, 15) . The log of this ratio (logDI) was then plotted against the quadrant tissue volume, which was obtained by multiplying the x and y quadrant dimensions by the confocal optical section thickness (100 m). Each image was further divided stepwise (4 ϫ 4, 8 ϫ 8,ѧ128 ϫ 128), and the particles within each subdivision were counted, averaged, and plotted against their respective subdivision tissue volumes. The values at each of the seven steps (2 ϫ 2ѧ 128 ϫ 128) were averaged among the eight images obtained from each lung. These averages were compared among treatment groups (each of the 4 vasoactive agents, and the High Flow and Low Flow controls).
Statistics. Results are expressed as means Ϯ SE. Data obtained in each 30 s perfusate sample (perfusate flows and venous particle effluent concentrations) were averaged within each treatment group (each vasoactive agent, and High Flow and Low Flow controls), and these averages were compared among treatment groups using repeatedmeasures analysis of variance. Post hoc tests were performed using Fisher's protected least significant difference test. We used similar methods to compare the particle concentrations in the venous effluents at each collection time and to compare confocal image analysis data at each of the seven tissue subdivisions. Differences were considered to be significant at P Յ 0.05.
RESULTS
Perfusate flows. Baseline perfusate flows averaged 5.73 Ϯ 0.22 ml/min in lungs of all groups and fell to 3.69 Ϯ 0.23 ml/min following vasoconstriction (Fig. 1) . These values did not differ among vasoconstricted groups and Low Flow controls, but were significantly lower than those the High Flow controls, which averaged 5.62 Ϯ 0.11 ml/min.
Venous effluent particle concentrations. Particle concentrations in venous effluents of lungs in High Flow controls averaged 4.2 Ϯ 1.1% at 0.5 min and 0.98 Ϯ 0.37% at 1 min after particle infusion, which was significantly higher than particle concentrations in all other groups at these two times (Fig. 2) . Particle concentrations in venous effluents of the U46619 group at 0.5 min averaged 0.64 Ϯ 0.16%, which was significantly higher than those in the effluents of the angiotensin (0.17 Ϯ 0.06%) or bradykinin (0.10 Ϯ 0.06%) groups. However, U46619 particle concentrations at this time were not significantly different from those in Low Flow controls (0.26 Ϯ 0.11%) or in the serotonin group (0.44 Ϯ 0.19%).
Particle trapping patterns. Examples of particle trapping patterns in air-dried lungs appear in Fig. 3 , where it is apparent that the patterns differed among treatment groups. To quantify these differences, we counted the total number of particles in high-magnification images like those shown in Fig. 3 and also measured the dispersion index of the particle patterns in those images, as described (METHODS). Numbers of particles per image were significantly higher in lung perfused with bradykinin, serotonin, or angiotensin II than in those perfused with U46619 or in High Flow or Low Flow controls (Fig. 4) . Dispersion index measurements (Fig. 5) show that particle clustering was greatest in the bradykinin group and, to a lesser extent, also in the serotonin and angiotensin groups, where the logDI values were significantly higher than those in the U46619 group and in the High Flow and Low Flow controls. High logDI values mean that the particle distributions were nonrandom (clustered), whereas small logDI values mean that the particle distributions were random (nonclustered). The high logDI values for the bradykinin, serotonin, and angiotensin lungs are consistent with the clustered appearances of the trapping patterns of the particles in those lungs (Fig. 4) .
DISCUSSION
The goal of our studies was to determine if we could find evidence for active control of perfusion within lung microvessels. We found that, although all four vasoconstrictor agents produced equal levels of flow reduction, they did not have equal effects on particle trapping. This suggests that each agent did not produce vasoconstriction by a common mechanism and supports our hypothesis that active control of perfusion may exist among microvessels.
We found that angiotensin II and bradykinin produced lower venous particle concentrations in the first venous effluent samples collected (at 0.5 min) than did the thromboxane analog U46619 (Fig. 2) . Furthermore, lungs perfused with angiotensin II, bradykinin, and serotonin had greater numbers of particles in confocal images (Fig. 3, high magnification; Fig. 4 ), and showed greater particle clustering in those images (Fig. 5) than did lungs perfused with U46619. The implication of these results is that angiotensin II, bradykinin, and serotonin produced vasoconstriction by a different mechanism than did U46619, although all four agents produced equivalent levels of vasoconstriction as judged by perfusate flows (Fig. 1) .
We interpreted our findings in terms of possible vasoconstriction mechanisms that might have produced these results (Fig. 6 ). Our interpretations were based on the assumption that vasoconstriction could have occurred in 1) vessels known to be surrounded by smooth muscle, namely arterioles, or 2) vessels lined with contracting endothelial cells or surrounded by pericytes, namely microvessels. We also considered a third possibility, namely that perfusion might be controlled by both arterioles and microvessels.
If constriction occurred in pulmonary arterioles, the majority of which have diameters larger than 85 m (scenario 1), active contraction by these vessels would not have narrowed the vessel bores enough to trap 3 m diameter particles within them (19) . Arteriolar contraction would, however, reduce downstream perfusion pressures and thereby reduce microvessel distension, and it is theoretically possible that diameters of the downstream microvessels would be reduced just as much as if active microvascular constriction had occurred within the microvessels. To duplicate the effect of arteriolar constriction, we lowered the height of the arterial reservoir in nonvasoconstricted lungs to match perfusate flows in vasoconstricted lungs (Low Flow group). Similarities in particle trapping between vasoconstricted lungs and Low Flow lungs would therefore suggest arteriolar and not microvascular constriction. However, if particle trapping in microvessels of vasoconstricted lungs differed from particle trapping in Low Flow lungs, it would suggest constriction in microvessels instead of arterioles. Concentrations are expressed as a percentage of the total number of particles infused (3 ϫ 10 6 ). At 0.5 and 1.0 min, the concentrations in the High Flow group were significantly higher than those in all others. The U46619 concentrations at 0.5 min were significantly higher than those in the angiotensin II and bradykinin groups. Fig. 3 . Confocal images of 3 m latex particle trapping patterns in lungs of each perfusate group. Bradykinin, serotonin, and angiotensin II produced greater particle clustering (Fig. 4) and greater numbers of particles in highmagnification images (Fig. 5) than did U46619 or High Flow or Low Flow controls.
If vasoconstriction occurred in microvessels surrounded by pericytes or lined with microvascular endothelial cells capable of contraction (scenario 2; INTRODUCTION), we assumed that the diameters of the constricted vessels would be small enough to directly impede the passage of 3 m diameter particles through them.
Our assumptions about particle diameters and microvascular calibers were based on results of our previous work in which we defined lung microvascular diameters in terms of the ability of latex particles of various diameters (0.24-to-10.0 m) to flow through isolated, perfused lungs (9 -11). Results of those studies conducted in nonvasoconstricted lungs in zone II (P PA Ͼ P Inf Ͼ P LA ), revealed that 67% of 2 m diameter particles were able to flow through the lungs, whereas only 2% of 4 m particles were able to flow through. Thus 3 m diameter particles were ideal for our present experiments, which were designed to reveal differences in particle trapping patterns among vasoconstricted lungs.
Based on those results, we assumed that 3 m diameter particles would flow through isolated, perfused lungs with little impediment in the absence of vasoconstriction, as in the conditions that existed in the High Flow group (Fig. 6A) . We assumed that such conditions (P PA ϭ 10, P insp /P exp ϭ 15/5 cmH 2 O) would produce high venous 3 m effluent particle concentrations (Fig. 2) , little retention of particles within the lung, and small numbers of particles in confocal images (Figs.  3 and 4) . We also assumed they would produce little particle clustering in those images (low logDI values; Fig. 5 ) because few particles would be retained. The results we obtained for the High Flow group are consistent with these assumptions of a lack of constriction among either arterioles or microvessels. Fig. 4 . Numbers of particles in confocal images. Particle numbers in confocal images of lungs perfused with bradykinin, serotonin, or angiotensin II were greater than images from lungs perfused with U46619 or High Flow or Low Flow controls (means Ϯ SE). Examples are the higher magnification images shown in Fig. 3 . Fig. 5 . Dispersion index (DI) analysis of particle trapping patterns in confocal lung images. DI analysis quantifies the clustering (nonrandomness) of particle trapping patterns in confocal lung images (means Ϯ SE) (7) . The method subdivides each image sequentially (2 ϫ 2, 4 ϫ 4,ѧ 128/128) and calculates the ratio of the variance ( 2 ) to the mean () of the number of particles in each subdivision (12) . The log of this ratio is shown on the y-axis. Higher values signify greater clustering. Image subdivisions are expressed on the x-axis in units of tissue volume. The data show that bradykinin caused the greatest clustering (highest logDI value), followed by serotonin and angiotensin II. Examples of analyzed images are the higher magnification images shown in Fig. 6 . Fig. 6 . Vasoconstriction models to explain latex particle trapping. In the High flow (nonvasoconstricted) model (A), 3 m diameter latex particles are assumed to flow through microvessels (from left to right), with little impediment. Arteriolar constriction alone (B) would reduce microvascular perfusion as a consequence of reduced perfusion pressure at the microvessels. Lowering the arteriolar reservoir (without vasoconstrictors) would do the same. Microvascular vasoconstriction alone (C) would narrow microvascular caliber, impede latex particle passage, and reduce venous effluent particle concentrations. A third possibility is that vasoconstrictors acted on both arterioles and microvessels simultaneously without acting independently on either (D).
If vasoconstriction occurred only within arterioles and not microvessels (Fig. 6B) , we assumed that flow of 3 m particles through microvessels would be impeded because of reduced perfusion pressure at the microvessels downstream from the arterioles. These are the conditions we simulated with the Low Flow group. We assumed that this would reduce the appearance of the particles in the venous effluent (Fig. 2) and also assumed that particles retained within the lung would be more dispersed (fewer particles per confocal image) and less clustered (low logDI values) than if vasoconstriction had occurred within microvessels, which we assumed would cause particles to accumulate within or immediately upstream of the microvessels. The absence of particle clustering in confocal images of Low Flow lungs (Figs. 3-5 ) combined with reduced venous particle concentrations in this group (Fig. 2) are consistent with our assumptions about the effects of lowering the arterial reservoir to match perfusate flows in vasoconstricted lungs.
We found a similar pattern in lungs perfused with the thromboxane analog U46619. Venous particle concentrations (Fig. 2) were not significantly different from those of the Low Flow group, and within-lung particle trapping patterns (Figs. [3] [4] [5] were also similar to those of the Low Flow group. This suggests that U46619 may have caused vasoconstriction through action on arterioles and not microvessels. Evidence supporting action of U46619 on arterioles is provided by results of studies demonstrating the ability of U46619 to induce contraction of isolated rat pulmonary arteries (2-3 mm diameter) and contraction of isolated piglet pulmonary arterioles (100 -400 m diameter) (13, 18) . U46619 induces contraction of vascular smooth muscle via activation of the Ca 2ϩ /calmodulin/MLCK pathway, and the RhoA/ROK pathway (23) .
If vasoconstriction occurred in microvessels but not arterioles (Fig. 6C) , we assumed that perfusion through microvessels would be impeded due to narrowing of the microvascular lumen. This would be expected to produce lower venous 3 m particle concentrations at 0.5 min than would arteriolar constriction, which would lower microvascular perfusion pressures but not produce microvascular constriction. Indeed, we found that angiotensin and bradykinin produced significantly lower venous particle concentrations at 0.5 min than did U46619 (Fig. 2) . Serotonin particle concentrations at this time were not significantly different from those of U46619. Particle clustering and numbers of particles per image for serotonin, angiotensin, and bradykinin were all significantly greater than those for U46619. This is consistent with the idea that these agents may have narrowed microvascular caliber more than did U46619.
An additional possibility is that vasoconstriction occurred in both arterioles and microvessels (Fig. 6D ). This would have produced lower venous effluent particle concentrations than either microvessel or arteriolar constriction alone. Serotonin might have functioned in this manner, which could explain why venous particle concentrations at 0.5 min tended to be higher than those for angiotensin and bradykinin (Fig. 2 ), yet retained particles were more clustered than those for U46619 (Figs. 3-5) .
Previous studies on the effects of these agonists on regional pulmonary vasoconstriction have been reported using the vascular occlusion method. In that method, which is conducted in nonventilated lungs in zone III, pressures in precapillary, postcapillary, and capillary segments are estimated from the shapes of pressure recordings obtained after selective occlusion of, respectively, the arterial cannula, the venous cannula, or both (21) . Vascular pressures change rapidly immediately following vascular occlusion (pressures fall or rise after arterial or venous occlusion, respectively), then change more slowly as perfusion drains (arterial occlusion) or fills (venular occlusion) the affected vascular segments. The inflection points between the rapid and slow phases of the pressure recordings are defined as the "precapillary" (arterial occlusion) or "postcapillary" pressures. Simultaneous occlusion of both capillaries provides the "capillary" or "middle segment" pressure. Anatomic equivalents and vessel diameters of these segments are not defined.
Using these methods, Gore and Jones (14) estimated that increases in vascular resistance caused by angiotensin II infusion into isolated, perfused rat lungs were approximately equally divided between the precapillary (47% of average resistance increase) and postcapillary segments (53% of average resistance increase) (14) . Infusion of serotonin into isolated dog lungs caused Barman (1) to conclude that the rise in vascular resistance was distributed as: 39% precapillary, 31% postcapillary, 31% within-capillary. Infusing the thromboxane analog U46619 into isolated rat lungs led Barnard and colleagues (3) to conclude that 70% of the resistance increase occurred within what they defined as the small-artery segment, and 23% occurred within the small vein segment. The balance (7%) presumably occurred within the capillary segment. Together, these studies suggest that these agonists produce vasoconstriction as a consequence of activity in pre-, post-, and within-capillary segments, although it appears that U46619 may have had its primary effect in the precapillary (arterial) segment.
Our latex particle method provides no information about degrees of resistance changes within individual pulmonary vascular segments, but it does provide information about the net change in resistance. For example, our results suggest that bradykinin, serotonin, and angiotensin had their greatest effects at the capillary level because these agents produced particle trapping patterns that were consistent with what would be expected of capillary constriction, namely particle clustering within or upstream of the capillaries. While these agents may have increased precapillary (arterial) and postcapillary (venular) resistances as well, constriction in neither of those segments would have caused increased particle trapping within microvessels, as the patterns in Fig. 3 suggest. Arteriolar constriction would have produced trapping patterns like those in our Low Flow group, which was designed to duplicate arteriolar constriction, and venous constriction would have caused capillary dilation, which would have reduced not increased particle trapping within microvessels. Particle trapping patterns in our U46619 studies support the vascular occlusion studies of Barnard and colleagues who concluded that 70% of the rise in vascular resistance occurred within the "small arterial" segment, upstream of the capillaries.
Evidence supporting the idea that pulmonary vasoactivity may be achieved through heterogenous mechanisms was recently reported by Casey and colleagues (5) who infused the Rho-kinase inhibitor (pulmonary vasodilator) Y-27632 into the lungs of intact rats. They found that Y-27632 reduced pulmonary artery pressures, even if those pressures were first increased by infusion of U46619, serotonin, or angiotensin II.
They concluded that the pulmonary vasodilator response of Y-27632 was independent of the physiological mechanisms of vasoconstriction, suggesting that Y-27632 may have acted on sites independent of those responsible for vasoconstriction.
We interpreted our experimental results in terms of possible differential mechanisms of vasoconstriction of arterioles and microvessels, but we cannot rule out the possibility that these agents may have also acted on pulmonary veins. Previous reports suggest that angiotensin II and U46619 cause modest venous constriction, while bradykinin causes modest relaxation (2, 4) . It is difficult to predict how such activity would have affected venous particle concentrations or clustering of retained particles, but it emphasizes that pulmonary microvascular perfusion may not be controlled by simple contraction and relaxation of arterioles.
In summary, we achieved equal levels of vasoconstriction, as judged by perfusate flows, in isolated rat lungs perfused with angiotensin, bradykinin, serotonin, or U46619. However, infusion of 3 m diameter latex particles into these lungs produced differences in venous particle concentrations and patterns of particle retention within the lungs. These results suggest that these agents did not produce vasoconstriction by a common mechanism. We do not have evidence to specifically define what those mechanisms are, but our data can be interpreted in support of the hypothesis that some of these agents (angiotensin II, bradykinin, and serotonin) may have caused vasoconstriction mainly within pulmonary microvessels, as suggested by previous reports, while the thromboxane analog U46619 may have acted mainly on arterioles (16, 17, 20, 22) . Traditionally, perfusion control within the lung has been thought to be mediated mainly by arteriolar constriction and dilation. Results of our present study suggest that this idea may have to be revised.
